Kathy Johnson Weiler - 16 Dec 2025 Form 4 Insider Report for Axogen, Inc. (AXGN)

Role
Director
Signature
/s/ Marc Began, as attorney-in-fact for Kathy Weiler
Issuer symbol
AXGN
Transactions as of
16 Dec 2025
Net transactions value
-$1,098,326
Form type
4
Filing time
17 Dec 2025, 16:25:04 UTC
Previous filing
20 Jun 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Weiler Kathy Johnson Director C/O AXOGEN, INC. 13631 PROGRESS BLVD.,, SUITE 400, ALACHUA /s/ Marc Began, as attorney-in-fact for Kathy Weiler 17 Dec 2025 0001979466

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AXGN Common Stock Options Exercise $128,466 +18,248 +277% $7.04 24,828 16 Dec 2025 Direct
transaction AXGN Common Stock Options Exercise $151,684 +21,825 +88% $6.95 46,653 16 Dec 2025 Direct
transaction AXGN Common Stock Sale $539,174 -18,248 -39% $29.55 28,405 16 Dec 2025 Direct F1
transaction AXGN Common Stock Sale $644,863 -21,825 -77% $29.55 6,580 16 Dec 2025 Direct F1
transaction AXGN Common Stock Sale $194,439 -6,580 -100% $29.55 0 16 Dec 2025 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AXGN Employee Stock Option (right to purchase) Options Exercise $0 -18,248 -100% $0.000000 0 16 Dec 2025 Common Stock 18,248 $7.04 Direct F2
transaction AXGN Employee Stock Option (right to purchase) Options Exercise $0 -21,825 -33% $0.000000 43,651 16 Dec 2025 Common Stock 21,825 $6.95 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $29.01 to $30.00 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
F2 Non-qualified stock option portion of the annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The grant fully vested on June 6, 2025, the one-year anniversary of the date of the grant.
F3 Option grant for joining the Issuer's Board of Directors. Options vest in three equal annual installments on the annual anniversary of the grant date with the first vesting date occurring on December 20, 2024.